Cleerly ISCHEMIA vs Viz RV/LV

Viz RV/LV, as part of the broader Viz.ai platform, offers a more dynamic and integrated user experience, including mobile access, AI-powered alerts, and a HIPAA-compliant communication platform for real-time care coordination. This facilitates faster decision-making and multidisciplinary collaboration in acute settings. Cleerly ISCHEMIA provides comprehensive web-based reports and PowerScribe integration, which is valuable for detailed analysis and reporting, but lacks the immediate, mobile-first, and collaborative features of Viz.ai.

While both tools offer significant clinical value in their respective domains, Cleerly ISCHEMIA provides a more comprehensive and predictive assessment of coronary artery disease, including non-invasive FFR estimation and detailed plaque characterization, which aids in personalized long-term treatment planning and risk stratification. Its validation shows a strong association with future adverse cardiovascular events. Viz RV/LV excels in rapid, acute risk stratification for pulmonary embolism, demonstrating a significant reduction in mortality, but its scope is more focused on a single, critical measurement for an acute event.

Both tools lack public pricing transparency, requiring direct contact for details. While Cleerly ISCHEMIA is billable under a Category I CPT code, which provides a clear reimbursement pathway, Viz.ai has also received CMS reimbursement for its AI solutions, indicating a viable financial model for hospitals. Without specific cost data for either, it is impossible to definitively determine which offers better value.

Viz RV/LV, as part of the Viz.ai One platform, demonstrates superior enterprise readiness due to its extensive integration capabilities with PACS, EHR, and cloud environments, supported by Microsoft Cloud for Healthcare. Its comprehensive platform includes over 50 FDA-cleared algorithms across multiple specialties and is deployed in a large number of hospitals, showcasing proven scalability and broad applicability within complex health systems. Cleerly ISCHEMIA is also enterprise-ready with FDA clearance, HIPAA compliance, and PowerScribe integration, but its deployment and integration ecosystem appear less expansive than Viz.ai's.

Cleerly ISCHEMIA demonstrates greater innovation by providing a comprehensive, non-invasive assessment of coronary artery disease, including non-invasive FFR estimation and detailed plaque characterization. This offers a deeper diagnostic insight into the functional significance of CAD and aims to reduce reliance on more invasive procedures. While Viz RV/LV's automation for rapid PE risk stratification is highly impactful for acute care, Cleerly's approach to fundamentally changing how chronic heart disease is diagnosed and managed represents a more profound technological and clinical paradigm shift.

Viz.ai offers more robust and transparent support and documentation resources, including a dedicated customer success team, 24/7 on-call clinical specialists, implementation experts, and a comprehensive online knowledge base with tutorials and troubleshooting. Cleerly provides client and patient support channels, but the breadth and depth of readily available support information and dedicated resources appear more extensive for Viz.ai.